Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer

PURPOSE: The addition of trastuzumab to adjuvant chemotherapy has improved the outcome of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. Uncertainty remains about the optimal timing of trastuzumab treatment. Therefore, we compared long-term outcome after concurrent versus se...

Descripción completa

Detalles Bibliográficos
Autores principales: Dackus, Gwen M. H. E., Jóźwiak, Katarzyna, van der Wall, Elsken, van Diest, Paul J., Hauptmann, Michael, Siesling, Sabine, Sonke, Gabe S., Linn, Sabine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921067/
https://www.ncbi.nlm.nih.gov/pubmed/33113088
http://dx.doi.org/10.1007/s10549-020-05978-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921067/
https://www.ncbi.nlm.nih.gov/pubmed/33113088
http://dx.doi.org/10.1007/s10549-020-05978-8

Ejemplares similares